39 assets in Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive

Therapeutic assets addressing Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Fludarabine Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive	Ohio State University Comprehensive Cancer Center	P2	BBB (73)
Cyclophosphamide Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive	Ohio State University Comprehensive Cancer Center	P2	BBB (72)
Imatinib Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive	The University of Hong Kong	P2	BB (71)
Tacrolimus Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive	University of Michigan Rogel Cancer Center	P2	BB (71)
Nilotinib Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive	The University of Hong Kong	P2	BB (70)
Dexasone Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive	OHSU Knight Cancer Institute	P2	BB (68)
(+)-Vincristine Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive	OHSU Knight Cancer Institute	P2	BB (68)
Cyclosporin A Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive	University of Michigan Rogel Cancer Center	P2	BB (67)
Methotrexate Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive	University of Michigan Rogel Cancer Center	P2	BB (66)
Nivestim Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive	M.D. Anderson Cancer Center	P2	BB (66)
Venetoclax Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive	M.D. Anderson Cancer Center	P2	BB (66)
Ponatinib Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive	M.D. Anderson Cancer Center	P2	BB (65)
Adriamycin Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive	OHSU Knight Cancer Institute	P2	BB (64)
Cytarabine Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive	M.D. Anderson Cancer Center	P2	BB (64)
Prednisone Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive	OHSU Knight Cancer Institute	P2	BB (64)
Rituximab Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive	OHSU Knight Cancer Institute	P2	BB (64)
Dasatinib Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive	The University of Hong Kong	P2	B (63)
Asciminib Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive	The University of Hong Kong	P2	B (60)
Blinatumomab Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive	Marlise Luskin, MD	P2	B (60)
Idarubicin Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive	M.D. Anderson Cancer Center	P2	B (60)
Dexrazoxane Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive	M.D. Anderson Cancer Center	P2	B (59)
Vorinostat Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive	OHSU Knight Cancer Institute	P1/2	B (57)
Cladribine Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive	M.D. Anderson Cancer Center	P2	CCC (53)
Gemtuzumab Ozogamicin Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive	M.D. Anderson Cancer Center	P2	CCC (53)
Gilteritinib Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive	M.D. Anderson Cancer Center	P2	CCC (53)
Midostaurin Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive	M.D. Anderson Cancer Center	P2	CCC (53)
Pegfilgrastim Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive	M.D. Anderson Cancer Center	P2	CCC (53)
Vincristine Sulfate Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive	Mayo Clinic	P2	CCC (53)
Car.70/Il15-Transduced Cb-Nk Cells Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive	M.D. Anderson Cancer Center	P1/2	CCC (48)
Orca-Q Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive	University of Florida	P1/2	CCC (48)
Anti-Pr1/Hla-A2 Monoclonal Antibody Hu8F4 Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive	M.D. Anderson Cancer Center	P1	CC (43)
cd22 car-transduced t cells Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive	Ohio State University Comprehensive Cancer Center	P1	CC (43)
cd8+ and cd4+ donor memory t-cells-expressing ha1-specific tcr Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive	Fred Hutchinson Cancer Center	P1	CC (43)
Edetate Calcium Disodium Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive	M.D. Anderson Cancer Center	P1	CC (43)
Selinexor Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive	Dana-Farber Cancer Institute	P1	CC (43)
Succimer Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive	M.D. Anderson Cancer Center	P1	CC (43)